GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca Pharma India Ltd (BOM:506820) » Definitions » Debt-to-Revenue

AstraZeneca Pharma India (BOM:506820) Debt-to-Revenue : 0.00 (As of Mar. 2024)


View and export this data going back to 2001. Start your Free Trial

What is AstraZeneca Pharma India Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

AstraZeneca Pharma India's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹18 Mil. AstraZeneca Pharma India's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹28 Mil. AstraZeneca Pharma India's annualized Revenue for the quarter that ended in Mar. 2024 was ₹15,328 Mil. AstraZeneca Pharma India's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.00.


AstraZeneca Pharma India Debt-to-Revenue Historical Data

The historical data trend for AstraZeneca Pharma India's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Pharma India Debt-to-Revenue Chart

AstraZeneca Pharma India Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.02 0.01 0.01 -

AstraZeneca Pharma India Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 - - - -

Competitive Comparison of AstraZeneca Pharma India's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, AstraZeneca Pharma India's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca Pharma India's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca Pharma India's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where AstraZeneca Pharma India's Debt-to-Revenue falls into.



AstraZeneca Pharma India Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

AstraZeneca Pharma India's Debt-to-Revenue for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(18.146 + 27.836) / 12955.282
=0.00

AstraZeneca Pharma India's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(18.146 + 27.836) / 15328.032
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


AstraZeneca Pharma India Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of AstraZeneca Pharma India's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


AstraZeneca Pharma India (BOM:506820) Business Description

Traded in Other Exchanges
Address
Outer Ring Road, Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Bangalore, KA, IND, 560 045
AstraZeneca Pharma India Ltd is engaged in the manufacture, distribution, and marketing of pharmaceutical products. Its only operating segment being Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation and Autoimmunity, Neuroscience and Infection and Vaccines.

AstraZeneca Pharma India (BOM:506820) Headlines

No Headlines